Searle/Pfizer To Co-Promote Celebra: NDA Filing Expected by Year-End
Executive Summary
Pfizer is making an upfront payment of $85 mil. to Searle as part of a co-promotion and development agreement to market Searle's Celebra (celecoxib) and a second generation cyclooxygenase-2 inhibitor in Phase II. Searle is seeking approval for the treatment of osteoarthritis, rheumatoid arthritis and pain.